---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-033300"
form_type: "8-K"
ticker: "MRKR"
cik: "0001094038"
company_name: "Marker Therapeutics, Inc."
filed_at: "2023-03-16T23:59:59+00:00"
generated_at: "2026-06-18T00:09:31.929745+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Chief Medical Officer Mythili Koneru resigns effective April 9, 2023

## Summary
- Mythili Koneru notified Marker Therapeutics of her resignation as Chief Medical Officer, effective April 9, 2023.
- No replacement or interim successor has been announced by the company.
- The departure removes a key clinical oversight role from the biotech firm.

## SEC filing metadata
- accession: 0001104659-23-033300
- form_type: 8-K
- ticker: MRKR
- cik: 0001094038
- company_name: Marker Therapeutics, Inc.
- filed_at: 2023-03-16T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1094038/000110465923033300/0001104659-23-033300-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1094038/000110465923033300/tm239491d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-033300
- JSON: https://secwatch.observer/filing/0001104659-23-033300.json
- Plain text: https://secwatch.observer/filing/0001104659-23-033300.txt

## Key facts
- Executive change
  Mythili Koneru resigned as Chief Medical Officer at Marker Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Medical Officer
  source text: On March 13, 2023, Mythili Koneru, Chief Medical Officer of Marker Therapeutics, Inc. (the “ Company ”), notified the Company of her intent to resign as Chief Medical Officer of the Company effective as of April 9, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1094038/000110465923033300/0001104659-23-033300-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.